Loading
A Chinese study that gave about 2,500 people without symptoms a blood test for lung, bowel, liver, stomach and gullet cancer.
ProSight (NCT06790355) is a single-arm interventional study sponsored by Shanghai Weihe Medical Laboratory Co., Ltd with Fudan University. It evaluated the feasibility of a blood test designed to detect lung, colorectal, liver, gastric and oesophageal cancer, which gives a binary result and predicts the signal origin.
The registry record, read on 29 October 2026, gives its status as completed, with 2,527 participants enrolled, a start on 1 March 2025 and primary completion on 31 August 2026.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/